Beovu (Brolucizumab)
What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Coming Soon – Save up to 85%
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prescription Required
-
Product Details
Description
Beovu, also recognized by its generic name Brolucizumab, is a prescription medication used to treat neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). As a human vascular endothelial growth factor (VEGF) inhibitor, Beovu works by blocking VEGF, which is known to promote the growth of new abnormal blood vessels in the eye. Administered through injections directly into the eye, Beovu may help manage the progression of wet AMD.
Fact Table
Formula
C57H81N15O19S
License
US FDA (2019)
Bioavailability
N/A (administered via intravitreal injection)
Legal status
Prescription only (?)
Chemical Name
Humanized single-chain variable fragment (scFv) monoclonal antibody
Elimination half-life
4.4 days (in the vitreous humor)
Dosage (Strength)
6 mg/0.05 mL solution for injection
Pregnancy
Not recommended (Category C)
Brands
Beovu
Protein binding
Not significant (low systemic exposure)
PubChem CID
167206340
MedlinePlus
a620019
ChEBI
CHEBI:164087
ATC code
S01LA06
DrugBank
DB14951
KEGG
D11072
Routes of administration
Intravitreal injection
Directions
Beovu is administered through an intravitreal injection, a procedure that delivers the medication directly into the eye. The dosage varies depending on the condition being treated. The standard initial dosage of Beovu is 6 mg (0.05 mL of a 120 mg/mL solution) every month for the first three doses for AMD or every six weeks for the first five doses for DME. After this initial phase, the dosage schedule may transition to one dose of 6 mg at extended intervals as recommended by a healthcare provider. The injections are typically done under the guidance of a retinal specialist to ensure safety and effectiveness.
Ingredients
The active ingredient in Beovu is Brolucizumab-dbll.
Contraindications
Avoid taking or using this medication if any of the following apply:
- Known allergy to Brolucizumab or any of the components in the formulation
- Infection in or around the eyes
- Active inflammation within the eyes
Cautions
- Consult a healthcare provider before starting Beovu about the following:
- Any medications you take
- Other medical conditions you have
- If you have any allergies to any medications
- Whether you’re pregnant or breastfeeding
- After receiving an injection of Beovu, there's a risk of developing endophthalmitis (an eye infection) and retinal detachment. Be vigilant for any symptoms like eye pain, redness, or vision changes, and report them immediately to your healthcare provider.
- Cases of retinal vasculitis (inflammation of the retinal vessels) and retinal vascular occlusion (blockage of retinal blood vessels) have been reported following Beovu injections. These conditions usually occur in the presence of intraocular inflammation. Any change in vision should be reported promptly.
- A rise in the pressure inside your eye can occur within 30 minutes of receiving Beovu. It's important to have your eye pressure checked as advised by your eye specialist.
- As with other VEGF inhibitors used in the eye, there's a potential risk of arterial thromboembolic events, such as stroke or heart attack, following the use of Beovu.
Side Effects
Beovu injections may cause certain side effects. The most common side effects include blurred vision, cataracts (clouding of the lens in the eye), bleeding in the white part of the eye, floaters (small specks or clouds moving in your field of vision), eye pain, increased eye pressure, and redness or irritation of the eye. Some patients also experience dryness or increased tearing, a feeling of something in the eye, and temporary changes in vision.
Beovu can lead to more serious eye problems, such as severe allergic reactions, infection inside the eye, detachment of the retina (the layer at the back of the eye), blockage of blood vessels in the retina, and increased eye pressure, which can lead to vision problems. It's important for patients to immediately report any sudden changes in vision, severe eye pain, or significant discomfort to their healthcare provider. Regular eye exams are crucial for those receiving Beovu treatment.
References:
- Beovu (Brolucizumab) Product Monograph. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023.
- Beovu (Brolucizumab) Drug Label Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 14547
-
Product Reviews
